Novartis’ proposed drug for adults diagnosed with a certain type of advanced prostate cancer was given the green light for commercialization.
Three companies – Intellia Therapeutics, Editas Medicine and uniQure – are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
Radiomics is a field of research in which image analysis is used to extract large number of quantitative features from medical images, such as MR, CT, and PET scans. While there are many potential applications of radiomics across the healthcare spectrum, oncology continues to be one of the main areas of study.
This paper looks at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them.
Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for the company’s Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D), a rare, progressive and debilitating disease marked by high levels of the amino acid arginine.
A late-stage trial of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach the study’s main goal, but secondary measures and biomarkers showed favorable trends, the company said on Oct. 17.
Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.
BioSpace takes a look at some of the top stories from day one of the Annual Biomarkers for Alzheimer’s Disease Summit held August 25-26, 2021.
In a review of recently published scientific studies, investigators at Keck School of Medicine of USC identified a natural barrier to the inner’s sensory cells’ ability to regenerate.